Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ketamine Clear all
Recruiting Early Phase 1 Interventional

Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer

NCT05086250
View directory record Official record
Conditions
Anxiety, Pancreatic Cancer
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 24, 2026, 12:47 AM EDT
Not listed Phase 4 Interventional

Pre-Operative Ketamine Infusion for Post Operative Pain Control After Revision Spinal Surgery

NCT06066879
View directory record Official record
Conditions
Revision Spine Surgery, Fusion of Spine, Cervical Fusion, Lumbar Fusion
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
AXIS Spine Center- a division of Northwest Specialty Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Coeur d'Alene, Idaho
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Jul 24, 2026, 12:47 AM EDT
Completed Phase 3 Interventional Results available

Peri-Operative Lidocane, Ketamine, or Lidocane and Ketamine Combination, Infusion for Patients Undergoing Spine Surgery

NCT01983020
View directory record Official record
Conditions
Postoperative Pain
Interventions
Lidocaine, Ketamine, Saline
Drug · Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Jul 24, 2026, 12:47 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 24, 2026, 12:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Low Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department

NCT01835262
View directory record Official record
Conditions
Pain
Interventions
Morphine, Ketamine
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Jul 24, 2026, 12:47 AM EDT
Completed Phase 4 Interventional Results available

Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries

NCT03470675
View directory record Official record
Conditions
Pain, Postpartum Depression
Interventions
Epidural saline + IV saline, Epidural morphine 3 mg + IV saline, Epidural morphine 3 mg + IV ketamine 0.3 mg/kg
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 24, 2026, 12:47 AM EDT
Enrolling by invitation Phase 3 Interventional Accepts healthy volunteers

GA + ESP vs. SA + ESP in Lumbar Decompression Surgeries

NCT05444751
View directory record Official record
Conditions
Lumbar Disc Herniation, Lumbar Disc Disease, Lumbar Radiculopathy
Interventions
General anesthetic, SA + ESP
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 24, 2026, 12:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

Ketamine Assisted Psychotherapy for Opioid Use Disorder

NCT04892251
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
MORE+KAP, MORE
Combination Product · Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced Jul 24, 2026, 12:47 AM EDT
Completed Phase 2 Interventional Results available

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

NCT02133001
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Esketamine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 24, 2026, 12:47 AM EDT
Completed Not applicable Interventional Results available

Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatment

NCT06139016
View directory record Official record
Conditions
Depression
Interventions
Virtual reality
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 24, 2026, 12:47 AM EDT
Active, not recruiting Phase 2 Interventional

Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment

NCT06069843
View directory record Official record
Conditions
Depression, Mild Cognitive Impairment
Interventions
IV Ketamine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
50 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Jul 24, 2026, 12:47 AM EDT
Completed Phase 2 Interventional Results available

Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients

NCT02106325
View directory record Official record
Conditions
Depression
Interventions
Ketamine, Diphenhydramine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Jul 24, 2026, 12:47 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Spine Surgery Analgesic Pathway

NCT02887404
View directory record Official record
Conditions
Posterior Spine Surgery
Interventions
Spine surgery analgesic pathway, Usual Care
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Jul 24, 2026, 12:47 AM EDT
Completed Not applicable Interventional Results available

Intranasal Ketamine in Treatment-Resistant Depression

NCT01304147
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, placebo
Drug
Lead sponsor
James Murrough
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Jul 24, 2026, 12:47 AM EDT
Active, not recruiting Phase 4 Interventional

Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression

NCT06317636
View directory record Official record
Conditions
Chronic Pain, Depression
Interventions
Ketamine, Normal saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jul 24, 2026, 12:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ketamine Infusion Therapy for PTSD in Combat Veterans

NCT03088384
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Ketamine
Drug
Lead sponsor
Klarisana Physician Services PLLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Jul 24, 2026, 12:47 AM EDT
Terminated Phase 4 Interventional Results available

Ketamine-assisted Therapy for Advanced GI Cancer

NCT06077487
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization
Interventions
Ketamine, Ketamine Injectable Product, Meaning and Purpose therapy, Placebo, Questionnaires
Drug · Behavioral · Other
Lead sponsor
Brian Anderson, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jul 24, 2026, 12:47 AM EDT
Completed Phase 2 Interventional Results available

Ketamine Plus Lithium in Treatment-Resistant Depression

NCT01880593
View directory record Official record
Conditions
Depression
Interventions
Lithium, Ketamine, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Jul 24, 2026, 12:47 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Sedatives on Tobacco Use Disorder

NCT03813121
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
midazolam intravenous infusion, placebo intravenous infusion, ketamine intravenous infusion
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Jul 24, 2026, 12:47 AM EDT
Completed Phase 4 Interventional Results available

A Comparison of Proprietary Formulations of Oral Ketamine + Aspirin and Oral Ketamine Alone for Musculoskeletal Pain

NCT04860804
View directory record Official record
Conditions
Pain
Interventions
Aspirin and Ketamine, Oral Ketamine
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Jul 24, 2026, 12:47 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Ketamine for OUD and Comorbid Depression (OUDCD)

NCT05051449
View directory record Official record
Conditions
Opioid Use Disorder, Depressive Disorder
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Jul 24, 2026, 12:47 AM EDT
Completed Phase 3 Interventional Results available

Ketamine to Prevent PPD After Cesarean

NCT04227704
View directory record Official record
Conditions
Postpartum Depression
Interventions
Ketamine 50 MG/ML, Control
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jul 24, 2026, 12:47 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 24, 2026, 12:47 AM EDT
Not listed Early Phase 1 Interventional

Ketamine for Mood Disorders With Suicidal Ideation

NCT04099771
View directory record Official record
Conditions
Depressive Disorder, Major, Suicidal Ideation
Interventions
Ketamine
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Jul 24, 2026, 12:47 AM EDT